New Studies Conclude Xlear Kills and/or Deactivates SARS-CoV-2
30.11.2020 11:00:00 EET | Business Wire | Press release
New in vitro studies, led by renowned authority on respiratory diseases, conclude Xlear nasal spray is “an effective...and replicable means to deactivate SARS-CoV-2...to an undetectable amount of infectious virus.” This conclusion is “validated by two independent sets of experiments, performed by different labs, on different viral strains...” The Virucidal studies were independently funded.
“The Virucidal Studies shed important light on the role Xlear can play in helping combat the COVID-19 pandemic,” said Dr. Gustavo Ferrer, who is leading the research team.
State of scientific research:
Nasal sprays, such as Xlear, reduce viral load in the nose, which is vital in fighting COVID-19. Research shows COVID-19 primarily infects and spreads through the upper respiratory system. By reducing viral load in the nose, nasal sprays help limit the severity and transmission of SARS-CoV-2 (COVID-19). https://jamanetwork.com/journals/jamaotolaryngology/fullarticle/2768627.
Xlear’s components are antiviral—they block viral adhesion in the nose. See, for example, https://www.biorxiv.org/content/10.1101/2020.08.19.225854v1.full.pdf. This Univ. of Tennessee study on SARS-CoV-2 concluded: “antiviral nasal sprays...contribute reduce...viral load...slowing down disease progression...and transmission...”
Peer-reviewed case studies indicate Xlear helps in treating COVID-19: First-look trial at Larkin Community Hospital (Miami), determined: “symptomatic, COVID-19 patients, treated with [Xlear], as an adjunct to...[standard care],” showed “rapid clinical improvement and shorten[ed] time” to negative COVID-19 PCR tests. https://www.cureus.com/articles/43909-potential-role-of-xylitol-plus-grapefruit-seed-extract-nasal-spray-solution-in-covid-19-case-series.
Xlear has been used for over 20 years by millions of people worldwide without a single significant adverse incident report.
“Building on the existing data, these Virucidal Studies show Xlear is not just antiviral, it is virucidal (kills/deactivates SARS-CoV-2). This combination of antiviral and virucidal capabilities is an important one-two punch in fighting the virus,” said Nathan Jones, CEO of Xlear. “With the pandemic raging worldwide, we must use every tool we can to fight it. Failing that needlessly risks millions of lives. Weighing our 20-year safety record, against the risks of this deadly virus, it’s clear Xlear needs to be in widespread use,” Jones concluded.
Full study: https://www.biorxiv.org/content/10.1101/2020.11.23.394114v1.full
More information on Xlear: https://xlear.com/
About Dr. Gustavo Ferrer
Dr. Ferrer, MD FCCP, is an Associate Professor of Medicine and Founder of the Cleveland Clinic Florida Interstitial Lung Disease Clinic and the Aventura Hospital Pulmonary and Critical Care fellowship. He currently serves as President of Intensive Care Experts/Aventura Pulmonary Institute and previously served as United Nations University Director of Respiratory Research, Venezuela.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201130005291/en/
Contact information
Jeff Gulko
617.304.7339
jeff@thegulkogroup.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Bial Reports Topline Results From ACTIVATE Phase 2b Study in GBA‑Associated Parkinson’s9.6.2026 09:00:00 EEST | Press release
Bial, an innovation-driven biopharmaceutical company focused on neurosciences and rare diseases, announced today that the Phase 2b ACTIVATE study of BIA 28-6156 (pariceract) in patients with Parkinson’s who have a pathogenic variant in the GBA1 gene (GBA-PD) did not meet its primary, nor the key secondary efficacy endpoints, meaning that BIA 28-6156 failed to slow the progression of GBA-PD versus placebo. BIA 28-6156 proved to be generally well tolerated in the study, with no unexpected safety concerns arising. While the study data provide valuable scientific information and contribute to a broader understanding of Parkinson’s biology, BIA 28-6156 did not demonstrate significant differentiation from placebo on the primary or key secondary endpoints measured. Based on the lack of demonstrated efficacy in this study, Bial has made the decision to discontinue further development of BIA 28-6156 for this indication. “We are disappointed with the outcome of the Phase 2b ACTIVATE study, as th
Avanzanite Expands into Spain and Appoints María Baquerizo as Country Manager9.6.2026 08:30:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today announced its expansion into Spain and the appointment of María Baquerizo López-Quectuy as Spain Country Manager. This follows a €32 million Series A investment by MVM Partners announced in November 2025 and the recent entry to France. Avanzanite’s continues to build its integrated European platform designed to accelerate access to innovative therapies for people living with rare diseases. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260608541655/en/ María Baquerizo López-Quectuy, Country Manager, Avanzanite Spain “Spain is an essential part of Avanzanite’s European vision,” said Adam Plich, Co-Founder and CEO, Avanzanite Bioscience. “The country combines scientific excellence, a sophisticated healthcare ecosystem and a large community of patients living with rare diseases who continue to
Cursor Announces EMEA Office and Team Expansion to Meet Regional Demand9.6.2026 08:00:00 EEST | Press release
Cursor, the leading multi-model AI coding platform, today announced the establishment of dedicated teams to serve the EMEA region. The expansion responds to regional momentum, with EMEA revenue tripling quarter over quarter this year. The Cursor EMEA team will support a rapidly expanding customer base that includes British Airways, BP, Deliveroo, Nokia, Sanofi and many other leading enterprises across the region. Cursor expects to grow its EMEA headcount to approximately 200 employees by the end of the year, hiring across go-to-market, engineering, customer success and operations. “We’re incredibly excited to officially launch Cursor across EMEA and deepen our commitment to customers and partners throughout Europe. As the leading AI coding company, our goal is simple: be closer to the teams building the future and help enterprises accelerate their most strategic AI and software development initiatives,” said Ismail Elmas, SVP of EMEA for Cursor. “This launch covers all major European m
Signaloid to Preview New ASIC and Demo of Its UxHw ® Technology at Bosch Connected World9.6.2026 08:00:00 EEST | Press release
British computing technology company Signaloid will preview its C0-ASIC for physical AI this week at Bosch Connected World, taking place from 10th-11th June, in Berlin. Designed for robotics, industrial automation, and probabilistic AI workloads, the ASIC is projected to deliver up to 1000× better performance-per-Watt than existing state-of-the-art approaches. Signaloid’s distribution-extended compute hardware (UxHw®) is already available for use in physical AI/robotics as a family of hardware modules, as well as via a virtualization- and binary-translation-based solution. UxHw enables autonomous mobile robots (AMRs) to improve their navigation algorithms for safer and faster navigation in factories. It similarly enables industrial programmable logic controllers (PLCs) to achieve better predictive maintenance. Why Physical AI and robotics needs different compute Many of the important algorithms enabling robotics and AI today require compute-intensive GPUs or similar hardware. They ofte
Hitachi and Google Cloud Expand Strategic Alliance to Accelerate Real-world Deployment of Physical AI Through FDE and Advanced Cybersecurity Solutions9.6.2026 03:20:00 EEST | Press release
Hitachi, Ltd. (TSE:6501, "Hitachi") today announced the expansion of its strategic alliance*1 with Google Cloud to support customers by accelerating the real-world deployment of physical AI and cybersecurity solutions to protect against AI generated threats. Garnering increasing attention, physical AI is a technology that connects AI-driven analysis and decision-making—derived from frontline data—to concrete actions such as autonomous control and operation of various devices and equipment. Continuously repeating this cycle enables optimal AI decision-making and execution tailored to each specific situation. Through the real-world deployment of physical AI, Hitachi is driving the transformation of social infrastructure. To realize this critical mission, through the strategic alliance, Hitachi will establish and globally deploy Hitachi's Forward Deployed Engineers (FDEs) model that leverages its strengths in IT, OT, and products cultivated through Lumada, together with Google Cloud’s adv
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom